Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Research Laboratories

Division of Eli Lilly & Co.

Latest From Lilly Research Laboratories

Set, Ready, Afford: China Rushes To Access Innovation Amid New Drug Dash

2018 is set to break the record for new drug approvals in China, which have included some immuno-oncology and powerful antiviral therapies. Providing access to these high-priced medicines to more patients in the populous country was high on the minds of several multinationals during a recent conference in Shanghai.

China Commercial

China Regulatory Express: New Essential Medicines Include Anticancers, HCV Combo

China has bolstered its reimbursement of important newer drugs for cancer and hepatitis C, offering full insurance coverage to six newer oncology products and a sofosbuvir combo through the latest update to its essential medicines list.

China Reimbursement

EU Approval Set For Three New Orphans And Lilly’s Emgality; Exondys Appeal Fails

The CHMP has upheld its previous negative opinion on Sarepta’s DMD treatment Exondys, but has given a raft of positive opinions on other novel products, including Lilly’s new migraine prophylactic Emgality, Spark Therapeutics’ gene therapy Luxturna for retinal dystrophy, and Vabomere, The Medicines Co/Rempex Pharmaceuticals’ new antibiotic for severe infections.

Europe Drug Review

EU Approval Set For Three New Orphans And Lilly’s Emgality; Exondys Appeal Fails

The CHMP has upheld its previous negative opinion on Sarepta’s DMD treatment Exondys, but has given a raft of positive opinions on other novel products, including Lilly’s new migraine prophylactic Emgality, Spark Therapeutics’ gene therapy Luxturna for retinal dystrophy, and Vabomere, The Medicines Co/Rempex Pharmaceuticals’ new antibiotic for severe infections.

Europe Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Eli Lilly & Co.
  • Senior Management
  • Pawel Fludzinski, VP, Global Reg. Affairs
    Michael McDonald, VP, Strategy
    August Watanabe, MD, Pres.
  • Contact Info
  • Lilly Research Laboratories
    Phone: (317) 276-2000
    Lilly Corporate Center
    Indianapolis, IN 46285
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register